Showing results (11-20 of 71) with videos related to
Sort By:
Pageof 8
Journal of Child and Adolescent Psychopharmacology|December 20, 2013
An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorderJustine M Kent, David Hough, Jaskaran Singh, et al.The Journal of Clinical Psychiatry|June 21, 2018
Relapse After Antipsychotic Discontinuation in Schizophrenia as a Withdrawal Phenomenon vs Illness Recurrence: A Post Hoc Analysis of a Randomized Placebo-Controlled StudyRobin Emsley, Isaac Nuamah, Srihari Gopal, et al.Schizophrenia Research|December 5, 2009
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studyDavid Hough, Srihari Gopal, Ujjwala Vijapurkar, et al.Schizophrenia Research. Cognition|March 11, 2020
Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety studyGahan Pandina, Isaac Nuamah, Timothy Petersen, et al.American Journal of Physiology. Gastrointestinal and Liver Physiology|July 12, 2014
Comparison of manual and semiautomated techniques for analyzing gastric volumes with MRI in humansAdil E Bharucha, Ronald A Karwoski, Jeff Fidler, et al.Neuropsychiatric Disease and Treatment|October 5, 2013
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studiesSrihari Gopal, Yanning Liu, Larry Alphs, et al.Journal of Child and Adolescent Psychopharmacology|July 29, 2015
Long-Term Safety of Paliperidone Extended Release in Adolescents with Schizophrenia: An Open-Label, Flexible Dose StudyAdam Savitz, Rosanne Lane, Isaac Nuamah, et al.Journal of Computer Assisted Tomography|February 28, 2008
Head-to-head comparison of oral contrast agents for cross-sectional enterography: small bowel distention, timing, and side effectsBrett M Young, Joel G Fletcher, Fargol Booya, et al.Current Medical Research and Opinion|June 24, 2011
Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)Chris M Kozma, Terra Slaton, Riad Dirani, et al.International Clinical Psychopharmacology|March 3, 2015
Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims databaseErica A Voss, Patrick B Ryan, Paul E Stang, et al.Pageof 8